LARS2

Across TCGA pan-cancer cohorts, LARS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LARS2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher LARS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LARS2 expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

COAD, LSCC, and CCRCC are the cancer types where LARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	II,III,IV	1.000	0.890	.023	36	view →
LSCC	DFS	Median	II,III,IV	0.899	0.492	<.001	24	view →
CCRCC	OS	Median	All	0.912	0.770	.034	3	view →
UCEC	DFS	Median	All	0.850	0.958	.022	2	view →
HNSC	DFS	Median	III,IV	1.000	0.937	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LARS2–COAD (DFS)

Open the COAD breakdown →